Structure Therapeutics’ Post

View organization page for Structure Therapeutics, graphic

4,892 followers

1mo

Our CEO Raymond Stevens recently spoke with CNBC Fast Money's Melissa Lee to discuss our progress with our #GLP1 receptor agonist drug, GSBR-1290, and its potential to become a best-in-class oral treatment for people living with #obesity, and the scalability of #smallmolecule drugs. Watch the full clip here: https://lnkd.in/eiuBxUz7

Structure Therapeutics CEO on GLP drugs

cnbc.com

2 Comments

Frédérique Badeaux

Responsable des plateformes au Centre de recherche du CHUS chez CIUSSS de l'Estrie - CHUS

It's awesome Ray. And great to hear you.

Huibin Yue

1mo

Well said, Raymond Stevens !

See more comments

To view or add a comment, sign in

More Relevant Posts

Jaime Gavazzi

Principal Content Writer/Editor (Medical)
6mo
Report this post
Check out my latest article, "FDA’s New Draft Guidance for Psychedelic Drugs Opens Doors for Drug Developers in the US," published in the Journal for Clinical Studies. Step by step... https://lnkd.in/dtqqimPZ
Like Comment
To view or add a comment, sign in
LucidQuest

6,100 followers
2mo
Report this post
Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew

https://endpts.com
Like Comment
To view or add a comment, sign in
American Society for Clinical Pharmacology & Therapeutics

8,054 followers
3mo
Report this post
Delve into a discussion with experts from FDA and industry about MIDD Strategies in RNA-Based Oligonucleotide Drug Development in this upcoming #ASCPTwebinar. 4/24 at 12 pm ET: https://bit.ly/49MdUxw
Like Comment
To view or add a comment, sign in
Dr. Timos Papagatsias

BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
3mo
Report this post
Thoughts on this? >> Neumora announces clinical hold from FDA on Phase 1 study for schizophrenia drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #productmarketing #biotech

FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits

https://endpts.com
Like Comment
To view or add a comment, sign in
Dr. Hafsa Jabeen

Intern at Osmania General Hospital | Medical coder | certified pharmacist in emergency medicine
10mo Edited
Report this post
Drug dose–response relationships are important in assessing the efficacy and potency of drugs. They are also useful for the interpretation of drug and receptor interactions. #Drugdose Medxury ®

2 Comments
Like Comment
To view or add a comment, sign in
BioDuro-Sundia

16,259 followers
1mo
Report this post
Peptide Drug Discovery Webinar One Week Away! Register Today: https://buff.ly/4ayEmKy Register today, and join us on Wednesday, Jun 19, 2024 at 10am ET / 7am PT / 4pm CET online to explore peptide drug discovery innovations in your preferred time zone. #Webinar #PeptideDrugDiscovery #PeptideDrugs #SyntheticPeptide #PeptidePlatform #DrugDiscovery
Like Comment
To view or add a comment, sign in
Chakib Rachedi, PharmD

Clinical Research | Drug Safety | Medical Affairs | Business Development
11mo
Report this post
🌍💊 #PharmaIndustry Update! Late-stage trial results disappoint Sumitomo Pharma (TYO: 4506) & Otsuka Pharma (TYO: 4578). The DIAMOND & DIAMOND 2 trials of ulotaront, a TAAR1 agonist for schizophrenia, showed negative outcomes. Nonetheless, the pursuit of innovative treatments continues. Connect & Follow for more info on the Pharma Industry WorldWide.🌍💪 #pharmacy #medicine #pharma #dz #algeria #MENA #globalhealth
Like Comment
To view or add a comment, sign in
Dr. Timos Papagatsias

BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
4mo
Report this post
Thoughts on this? >> Ionis touts PhII MASH study data that feature its DGAT2 antisense inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #healthcare #pharma

Ionis touts PhII MASH study data that feature its DGAT2 antisense inhibitor

https://endpts.com
Like Comment
To view or add a comment, sign in
WuXi AppTec, Laboratory Testing Division

4,958 followers
7mo
Report this post
The novelty, complexity and evolving regulatory guidance of oligonucleotide (oligo) therapies can create greater technical challenges for drug development than conventional drugs, but the right laboratory partner and technology can alleviate those challenges. Learn how to tackle the challenges of metabolite profiling and identification for oligo drug development. #MetID #oligonucleotide #Drugdevelopment https://hubs.li/Q027Lw-m0
Like Comment
To view or add a comment, sign in

4,892 followers

View Profile Follow

Structure Therapeutics’ Post

More Relevant Posts

Explore topics